Reports from Zhengzhou University Provide New Insights into Acute Myeloid Leukemia (A Retrospective Study On Effectiveness of Combined Recombinant Human Interferon-alpha-1b, Interleukin-2, and Thalidomide for the Treatment of Acute Myeloid ...).

This study observed the efficacy and safety of this regimen in the treatment of numbers of AML patients in various disease states." Keywords: Zhengzhou; People's Republic of China; Asia; Acute Myeloid Leukemia; Antiinfectives; Antineoplastics; Biological Factors; Cancer; Carboxylic Acids; Cytokines; Drugs and Therapies; Genetics; Health and Medicine; Hematology; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Interleukin-2; Interleukins; Leprostatics; Leukemia; Lymphokines; Myeloid Leukemia; Oncology; Organic Chemicals; Peptides; Pharmaceuticals; Phthalimides; Proteins; Thalidomide; Thalidomide Therapy EN Zhengzhou People's Republic of China Asia Acute Myeloid Leukemia Antiinfectives Antineoplastics Biological Factors Cancer Carboxylic Acids Cytokines Drugs and Therapies Genetics Health and Medicine Hematology Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Interleukin-2 Interleukins Leprostatics Leukemia Lymphokines Myeloid Leukemia Oncology Organic Chemicals Peptides Pharmaceuticals Phthalimides Proteins Thalidomide Thalidomide Therapy 2023 FEB 20 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology - Acute Myeloid Leukemia. Sixty patients with primary AML who were unable to receive chemotherapy, or with relapsed/refractory AML, showed a total response rate of 28.3% (17/60) after receiving the ITI regimen. [Extracted from the article]